Fox Corporation Free cash flow increased by 323.4% to $1.77B in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 9.0%, from $1.94B to $1.77B. Over 4 years (FY 2021 to FY 2025), Free cash flow shows an upward trend with a 8.6% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
An increase suggests improved operational efficiency or reduced capital intensity, providing more flexibility for capital allocation. A decrease may indicate higher investment in R&D or infrastructure, or potential challenges in converting earnings into cash.
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and m...
Large-cap medical device and pharmaceutical peers typically maintain strong, positive free cash flow, though levels vary based on the intensity of R&D spending and the lifecycle stage of major product lines.
free_cash_flow| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $622.00M | -$24.00M | -$753.00M | $1.54B | $817.00M | $196.00M | -$610.00M | $1.48B | $373.00M | -$70.00M | -$615.00M | $1.39B | $787.00M | $94.00M | -$436.00M | $1.94B | $1.39B | -$234.00M | -$791.00M | $1.77B |
| QoQ Change | — | -103.9% | <-999% | +304.1% | -46.8% | -76.0% | -411.2% | +343.3% | -74.9% | -118.8% | -778.6% | +326.5% | -43.5% | -88.1% | -563.8% | +545.2% | -28.2% | -116.8% | -238.0% | +323.4% |
| YoY Change | — | — | — | — | +31.4% | +916.7% | +19.0% | -3.4% | -54.3% | -135.7% | -0.8% | -6.1% | +111.0% | +234.3% | +29.1% | +39.3% | +77.1% | -348.9% | -81.4% | -9.0% |